Johnson & Johnson shows a stable financial performance with diversified healthcare products spanning pharmaceuticals, consumer health, and medtech. Despite challenges in the broader market, its fundamentals depict resilience and potential for steady growth.
Johnson & Johnson presents a strong overall rating with key strengths in return metrics despite some concerns in its valuation ratios.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Comparison of current and past ratings shows consistent performance with little variation in critical scores.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-24 | 3 | 4 | 5 | 5 | 2 | 1 | 1 |
| Previous | 0 | 4 | 5 | 5 | 2 | 1 | 1 |
Analyst consensus suggests a stable price target range with limited downside risk.
| High | Low | Median | Consensus |
|---|---|---|---|
| 166 | 162 | 164 | 164 |
The sentiment from analysts remains positive, with a predominant number of buy recommendations.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 17 | |
| Hold | 14 | |
| Sell | 3 | |
| Strong Sell | 0 |
Johnson & Johnson remains a resilient entity within the healthcare sector, with strong fundamentals and a diverse product portfolio. The company faces some valuation challenges but maintains solid return metrics, making it an attractive option for long-term investment. Analysts remain optimistic, highlighting potential stable growth with moderate risk factors. Overall, JNJ looks well-poised to navigate future market dynamics with steady performance.
This HTML snippet is designed to be easily embedded into a webpage and optimized for mobile viewing with headers, structured content, and responsive images while avoiding inline CSS except for the score-bar div components.